• About Genor
    • About Us
    • Vision & Mission
    • Our People
    • Our History
  • Research & Development
    • Integrated Platform
    • Pipeline
    • Manufacturing
    • Antibody Platform
  • Media
    • Corporate News
  • Investor Relations
    • Announcements
    • Corporate Governance
    • Stock Information
    • Presentations
    • Financial Reports
    • Investor Events
    • IR Contact
  • Contact
    • Investor Relations
    • Media Relations
    • Report An Adverse Event Relating To Our Medicines
    • Contact Us
EN | 简 | 繁
We are dedicated to become a biopharmaceutical company with global presence, serving patients and society.
Latest News
Latest News
  • 2022-06-24
    Genor Biopharma and Abogen Biosciences Announce a Cooperative Development Agreement to Jointly Develop Globally Innovative mRNA Products and Related Pharmaceuticals
  • 2022-06-06
    Genor Biopharma obtains IND approval from NMPA to commence the phase I/II clinical trial of GB263T, the world's first EGFR/cMET/cMET tri-specific antibody
  • 2022-05-24
    Genor Biopharma obtains IND approval to commence the phase I/II clinical trial of GB261
Read More
Find Out More
Research & Development
Research & Development
Pipeline
Pipeline
Manufacturing
Manufacturing
  • About Genor
    • About Us
    • Vision & Mission
    • Our People
    • Our History
  • Research & Development
    • Integrated Platform
    • Pipeline
    • Manufacturing
    • Antibody Platform
  • Media
    • Corporate News
  • Investor Relations
    • Announcements
    • Corporate Governance
    • Stock Information
    • Presentations
    • Financial Reports
    • Investor Events
    • IR Contact
  • Contact
    • Investor Relations
    • Media Relations
    • Report An Adverse Event Relating To Our Medicines
    • Contact Us
Logo
 | Developed by Euroland IR